Trial ID or NCT#



not recruiting iconNOT RECRUITING


This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.

Official Title

Multicenter, Randomized, Double-blind, Parallel-group Extension to Study AC-058B201 to Investigate the Long-term Safety, Tolerability, and Efficacy of Three Doses of Ponesimod, an Oral S1P1 Receptor Agonist, in Patients With Relapsing-remitting Multiple Sclerosis

Eligibility Criteria

Ages Eligible for Study: 18 Years to 55 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Jeffrey Dunn, MD
Jeffrey Dunn, MD
Multiple sclerosis specialist, General neurologist
Clinical Professor, Neurology & Neurological Sciences
Y. Joyce Liao, MD, PhD
Y. Joyce Liao, MD, PhD
Neuro-ophthalmology specialist
Professor of Ophthalmology and of Neurology

Contact us to find out if this trial is right for you.


Angela Campbell
(650) 721-6188